Chao, Richard C.

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 1,304

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation

Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., et al. (2022) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 1,061

Institutional implementation of clinical tumor profiling on an unselected cancer population

Sholl, L. M., Do, K., Shivdasani, P., Cerami, E., Dubuc, A. M., Kuo, F. C., Garcia, E. P., Jia, Y., Davineni, P., Abo, R. P., et al. (2016) · JCI Insight

Cancer Genomics and DiagnosticsGenomics and Rare Diseases

Cited by 450

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS G12C Solid Tumors (KRYSTAL-1)

Ou, S.-H. I., Jänne, P. A., Leal, T. A., Rybkin, I. I., Sabari, J. K., Barve, M. A., Bazhenova, L., Johnson, M. L., Velastegui, K. L., Cilliers, C., et al. (2022) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 322

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

Jänne, P. A., Rybkin, I. I., Spira, A. I., Riely, G. J., Papadopoulos, K. P., Sabari, J. K., Johnson, M. L., Heist, R. S., Bazhenova, L., Barve, M., et al. (2020) · European Journal of Cancer

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 140

99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation

Riely, G. J., Ou, S.-H. I., Rybkin, I., Spira, A., Papadopoulos, K., Sabari, J. K., Johnson, M., Heist, R. S., Bazhenova, L., Barve, M., et al. (2021) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 77

KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with colorectal cancer (CRC) and other solid tumors harboring a KRAS G12C mutation

Johnson, M. L., Ou, S. H. I., Barve, M., Rybkin, I. I., Papadopoulos, K. P., Leal, T. A., Velastegui, K., Christensen, J. G., Kheoh, T., Chao, R. C., et al. (2020) · European Journal of Cancer

Colorectal Cancer Treatments and StudiesProtein Kinase Regulation and GTPase Signaling

Cited by 77

A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.

Papadopoulos, K. P., Ou, S.-H. I., Johnson, M. L., Christensen, J., Velastegui, K., Potvin, D., Faltaos, D., & Chao, R. C. (2019) · Journal of Clinical Oncology

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 37

Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients

Paweletz, C. P., Heavey, G. A., Kuang, Y., Durlacher, E., Kheoh, T., Chao, R. C., Spira, A. I., Leventakos, K., Johnson, M. L., Ou, S.-H. I., et al. (2023) · Clinical Cancer Research

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 23